Public Comment Form for QIBA Documents

Notes:

- 1. **Initials** identify the commenter to facilitate clarification of the issue and/or communication of the resolution.
- 2. Priority
 - L: Low. Typo or other minor correction that an editor can manage; requires no group discussion.
 - M: Medium issue or clarification. Requires discussion, but should not lead to long debate.
 - **H**: High. Important issue where there is a major issue to be resolved; requires discussion/debate.
- 3. **Line** # shows exactly where in the original document the issue occurs, and is necessary for sorting.
- 4. **Section** # shows in which section the issue occurs (e.g., 4.1.2)
- 5. **Issue**: Describe your issue; include enough to indicate what you see as a problem.
- 6. **Proposal**: Propose a resolution to your issue, e.g., suggested new wording or description of a way to address the issue; leave blank if no resolution can be provided.

Document Filename: QIBA FDG-PET/CT as an Imaging Biomarker Measuring Response to Cancer Therapy v1.03

Public Comment Review Period: 17Jan2013 – 15Feb2013

Cmnt	Your Initials	Priority L M H	Line # (Please indicate either Line # or Section #)	Section #	Issue	Proposal	Leave Blank
1	SB	M	291	3.1.2.3	refraining from reading is not necessary for WB oncology imaging	remove this	Keep wording as is., due to concern of increased activity of neck musculature during reading.
2	SB	M	294	3.1.2.3	what is the justification for preventing patients voiding for 30mins after injection?		
3	SB	Н	297 & 305	3.1.2.3	strongly disagree. Catheterization often leads to pockets of concentrated urine. Bladder washouts increase dose to staff. Invasive and unnecessary	remove this	
4	SB	M	309	3.1.2.3	ideally sedation should be given for the scan duration and not the uptake period	include this comment in the text	
5	esp	М-Н	315+	3.1.2.3	Does height need to be measured post baseline?		
6	LP &SB	Н	365 & 646	3.2 & 3.6.3	we disagree that subsequent scans can be done on a different scanner as it is not possible to demonstrate equivalence	scans should be rescheduled if possible or the patient excluded from the study	
7	SB	M	377	3.2	Don't like this phase, the scan is still 'diagnostic' just not full-dose high resolution.	Suggest omitting this phase or state "fully diagnostic" CT scan	

Cmnt	Your Initials	Priority L M H	Line # (Please indicate either Line # or Section #)	Section #	Issue	Proposal	Leave Blank
8	SB	M	381	3.2	Strategy 2a preferred as it avoids any impact of contrast on quantitation unless a time interval is specified between contrast and PET	include note that this is the preferred strategy	
9	SB	Н	397	3.2	it may not be practical to only employ one imaging strategy in a clinical trial depending on local protocols and facilities. e.g. in some of our trials we require CE-CT, but this can be done as part of the PET study or as a separate CT study	clarify that strategy 2a and 2b should not both be used within a clinical trial, but strategy 1 plus a separate CE-CT can be used with strategy 2a to allow sites that do not have the facility to perform CE-CT in the PET centre	
10	esp	М-Н	433	3.2.1.1	Intra document consistency issue	Text indicates +/- 15 minutes as acceptable while tabular text indicates +/- 10 minutes	
11	LP	M	524	3.3.1	PET voxel size – not all current scanners can do 3-4mm voxels without reducing the FOV. The GE DST without Dimension console upgrade can only recon to 128x128 matrix = 4.7mm voxels.	change 3-4mm to being IDEAL and make target <5mm. UNLESS the idea is to exclude older generation scanners from clinical trials	
12	SB	M	Table	3.3.2	it says quantitative analysis should only be performed on unprocessed images – what about studies where the PET and CT need registered i.e. patient movement?	Clarify if these images should be excluded from analysis	
13	LP	M	552	3.3.3	no mention of storage of RAW data – this has proved invaluable in cases where recons have not been done correctly. Not difficult to store on modern systems	provide recommendations or say the clinical protocol should indicate if raw data should be stored locally	
14	NPL (JK)	Н	657 (Tabl e)	3.6.3.1.	the objective of the constancy test is to check for instrumental drift, and thus the deviation or bias from a traceable activity is irrelevant. Indeed, one does not even need to know the activity accurately. All one needs to measure is the ionisation current. What is important is that the reading is constant over time (after appropriate decay corrections). The "bias" from the expected value is then monitored via the "Accuracy" parameter, which is set to 2.5%.	the constancy limits should be MUCH tighter than 2.5%, or even better that the limits are decided form a statistical analysis of historical measurements, via a control (or Shewart) chart, with appropriately defined action limits and control limits etc. For the chambers we use at NPL, the standard deviation is more like 0.1%, going back over decades. My guess is that for clinical instruments the limits would be more like 0.5%	
15	LP	Н	657 (Tabl e)	3.6.3.1.	for the accuracy test in the UK, sites do an annual F-18 intercomparison with the primary standard at NPL so the calibrator factor is traceable	An annual F-18 intercomparison with NIST/NPL should be allowed in place of monthly measurements with a traceable source	
16	LP	M	660	3.6.3.1.	is it necessary to have calibration of stadiometers to this level if not using height to adjust SUV	suggest if not using for SUV, calibration at installation is sufficient	
17	LP	M	710	3.6.4	the phantom tests are not easy to follow	include a summary table with all the test	

Cmnt	Your Initials	Priority L M H	Line # (Please indicate either Line # or Section #)	Section #	Issue	Proposal	Leave Blank
	LP	Н	710	3.6.4	in the UK no-one owns the ACR phantom	names, frequency and a reference to the section with the description could the Jasczak phantom which is widely	
18					1	available be used as an alternative for the resolution measurements?	
19	RW/ esp	М-Н	784	3.6.5.3	PERCIST criteria uses SUL metric for minimum threshold determination; suggest revise multiplier for SUV utility in this regard and add disclaimer. 1.7 times liver was in recognition that PERCIST 1.5 x Liver + 2xSD may be a bit high for some less FDG avid tumors.	To maintain consistency with PERCIST, suggest using 1.9 x SUV liver would be more consistent. That said, about 5-10 % of cases may be un-evaluable at the 1.9 x liver as they are not hot enough Maybe it could be stated that "less FDG avid lesions than the evaluable threshold of 1.9 x liver may still be studied, but caution is in order, as their low initial FDG uptake may make changes in SUV less informative."	
20	LP	M	843	4.1	CT scanner calibration – if sites are already scanning a uniform Ge-68 cylinder daily to check the PET calibration could the CT be checked using this phantom (HU will obviously be different, but uniformity and output can be checked) and the water equivalent weekly		
21	LP	Н	843 & 891	4.1 & 4.2	PET calibration should be checked daily with a phantom and ideally tracked in the DICOM header	daily scan of Ge-68 cylinder should be performed	
22	esp	L-M	847- 850	4.2	Informative text is not located with the correlative content in tabular format	Consider relocating informative text regarding SW versioning to Section 4.5	
23	LP	L	858	4.2	incorrect DICOM tag	change "acquisition time" to "series time"	No, Reference field name is correct, DICOM tag is in error (changed to 0008 0032). ADDED new comment to improve explanation in text.
24	TC	М-Н	857- 860		Provide clearer explanation of the terms used and DICOM cross-reference.	Raised on TC call of 08Mar – PK/DC fup.	
25	LP	M	892	4.2	PET Scanner calibration: This test is not clear, it has the same name as the routine Qc tests in the previous table, there is no frequency or activity specified for the PET calibration. Is this referring	Clarification of what this test is for	

	Your	Priority	Line #	Section #	Issue	Proposal	Leave
	Initials	L M	(Please indicate				Blank
		Н	either Line # or				
			Section #)		to cross-calibration? If not, what is the		
					justification for using a 60 min + acquisition for		
					PET scanner calibration?		
	LP	Н	892	4.2	PET Scanner calibration: on GE and Siemens		
					systems there are likely to be jumps bigger than		
26					this if the manufacturers protocol is followed.		
					(GE quarterly cross-calibration and after source		
					Ge-68 cylinder change on Siemens)		
27	LP	M	892	4.2	SUV should be displayed on the scanner		
21					workstation to 2d.p		
	LP	M	892	4.2	Decay correction methodology: Wish to have a		
28					DICOM field to indicate if data is derived or		
					original. Series date/time should not be altered		
	LP	M	892	4.2	on derived series Bed position Temporal Differences: Should		
	LI	IVI	092	4.2	include time per bed (0018, 1242)		
29					ActualFrameDuration. Desirable to include slice		
					overlap		
	AS	M	892	4.2	PET-CT Alignment: are mobile PET/CT	Mobile PET-CT scanners often can not be as	
30					scanners expected to be covered in this profile,	well aligned as stationary ones – may want to	
					and expected to be within +/- 2mm alignment?	consider a looser specification.	
	AS	M	892	4.2	PET Radiation Dose: Does a DICOM	If it does, give clear reference to the	
31					Radiopharmaceutical Administration Radiation	specification.	
	AS	3.7	002	4.0	Dose Structured Report actually exist?	C1 111 11	
	AS	M	892	4.2	PET Voxel Size: Is range truly 3-4 mm in x- and y-directions, or is this meant to be BETTER	Shall be able to reconstruct PET voxels with a size of 4 mm or better in all three	
32					THAN 3 to 4 mm. In other words, would a	dimensions	
					reconstruction pixel size of 2.5 mm work?	difficusions	
	AS	M	892	4.2	Documentation of Exam Specification: Does	Make modalities clear in this description.	
33					this specification apply to both PET and CT?	F	
34	LP	M	901	4.3	Should have DICOM field to indicate if TOF and		
34					resolution recovery are on or off		
	LP	M	901	4.3	Reconstruction parameters: Should be in		
					DICOM header (0054, 1103)		
35					ReconstructionMethod and (0018, 1210)		
					convolutionKernel. Desirable to have iterations		
					and subsets		
	LP	L	924	4.4.1	ROI output stats: SUV is unitless	delete g/ml	No. While SUV is
36	21		/2.	11111	Troi output states. Se v is unitiess	defete g/ iiii	unitless, when use

Cmnt	Your Initials	Priority L M H	Line # (Please indicate either Line # or Section #)	Section #	Issue	Proposal	Leave Blank
							formula, do get units. Additional explanatory text to be inserted into document to address this issue.
37	esp	M	925+	4.4.1	ROI Output Statistics row: modify a specification to allow user flexibility without minimizing manufacturer requirement	Insert 'have the capability' so that it reads "Shall have the capability to output results with at least two decimal places."	
38	AS	M		4.4.3	DICOM Compliance: not clear what "transferable" means. Can this be made more clear?	Perhaps list equipment that image data will be transferred to: PACS, HIS, RIS, etc.	
39	esp	М-Н	1073	App. A	Need to insert list of members	TBD by chairpersons / RSNA staff	List of TC members to be provided by RSNA staff for insertion
40	PM	Н	1169	Appendi x C	SUV is dimensionless, there should be a density term in the definition of SUV		
41	esp	М-Н	1205- 1212	App. C	The document indicates that guidelines for response criteria threshold by SUV change is beyond scope, then indicates these threshold in this Section which is inconsistent	Either insert disclaimer language in this Section or delete these specific threshold statements for PMR, CMR, PMD, SMD	
42	AS	M		Various	Vendors will need standards in order to implement specifications in gray boxes. Examples are interfacing to blood glucose, weight, etc. measurement machines, and those that require DICOM fields that don't exist, yet.	Progress on standards adoption as it relates to this QIBA profile will need to be dynamic and tracked. Perhaps put a link on the website where this Profile will be stored?	
43	AS	M	1451-	Apdx F Regarding DRO	Better description of how exactly partial volume effects are incorporated into the phantom to make it easier for external groups to self-validate.	Provide more details such that internal institution tests can be developed and run.	
44	AS	M	1451-	Apdx F Regarding DRO	Not enough detail in Fig. 2's Table.	Useful if table extended with acceptable ranges for all values (the columns in the table).	

Add lines as needed.

Please leave the first and last columns blank. The committee will use the first column to number comments and the last column to record resolution.

Thank you for your comments!